Discovery of a novel series of selective HCN1 blockers |
| |
Authors: | McClure Kelly J Maher Michael Wu Nancy Chaplan Sandra R Eckert William A Lee Dong H Wickenden Alan D Hermann Michelle Allison Brett Hawryluk Natalie Breitenbucher J Guy Grice Cheryl A |
| |
Affiliation: | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, United States. kmcclure@its.jnj.com |
| |
Abstract: | The discovery of a series of novel, potent, and selective blockers of the cyclic nucleotide-modulated channel HCN1 is disclosed. Here we report an SAR study around a series of selective blockers of the HCN1 channel. Utilization of a high-throughput VIPR assay led to the identification of a novel series of 2,2-disubstituted indane derivatives, which had moderate selectivity and potency at HCN1. Optimization of this hit led to the identification of the potent, 1,1-disubstituted cyclohexane HCN1 blocker, 2-ethoxy-N-((1-(4-isopropylpiperazin-1-yl)cyclohexyl)methyl)benzamide. The work leading to the discovery of this compound is described herein. |
| |
Keywords: | HCN1 HCN4 Ion channel VIPR assay Strecker reaction Spared nerve injury model Analgesic Bradycardia Neuropathic pain |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|